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ABSTRACT
Objective To evaluate the effects of a community based
integrated intervention for early prevention and
management of chronic obstructive pulmonary disease
(COPD) in China.
Design Cluster randomised controlled trial.
Setting Eight healthcare units in two communities.
Participants Of 1062 people aged 40-89, 872 (101 with
COPD and 771 without COPD) who fulfilled the inclusion
andexclusioncriteriawereallocatedtotheinterventionor
the usual care programmes.
Intervention Participants randomly assigned to
integrated intervention (systematic health education,
intensive and individualised intervention, treatment, and
rehabilitation) or usual care.
Main outcome measures Annual rate of decline in forced
expiratory rate in one second (FEV1) before use of
bronchodilator.
Results Annual rate of decline in FEV1 was significantly
lower in the intervention community than the control
community, with an adjusted difference of 19 ml/year
(95% confidence interval 3 to 36) and 0.9% (0.1% to
1.8%) of predicted values (all P<0.05), as well as a lower
annual rate of decline in FEV1/FVC (forced vital capacity)
ratio (adjusted difference 0.6% (0.1% to 1.2%) P=0.029).
There were also higherrates of smokingcessation (21% v
8%, P<0.004) and lower cumulative death rates from all
causes(1%v3%,P<0.009)intheinterventioncommunity
thanin the controlcommunityduringthe fouryearfollow-
up. Improvements in knowledge of COPD and smoking
hazards, outdoor air quality, environmental tobacco
smoke, and working conditions were also achieved (all
P<0.05). The difference in cumulative incidence rate of
COPD (both around 4%) and cumulative death rate from
COPD (2% v 11%) did not reach significance between the
two communities.
Conclusions A community based integrated intervention
can have a significant impact on the prevention and
management of COPD, mainly reflected in the annual rate
of decline in FEV1.
Trial registration Chinese Clinical Trials Registration
(ChiCTR-TRC-00000532).
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) has
become a major public health problem worldwide
because of its highand increasing prevalence, morbid-
ity, and mortality.
12A recent report estimated that the
global prevalence of COPD (stage II or over) is about
10% (12% in men and 9% in women).
3 In China,
COPD affects 8% of the population aged 40 or
above
4 and is one of the top diseases in the World
Health Organization’s ranking of burden of diseases.
5
It is therefore necessary to develop a reliable inter-
vention strategy for prevention and management of
COPD to reduce the burden of this disease.
Current interventions for COPD (such as smoking
cessation, rehabilitation, nutrition support, drug treat-
ments,andpsychosocialaids)aremainlycarriedoutin
hospitals on a case by case basis among patients who
have already developedmoderatelyor severely symp-
tomatic COPD, while little attention has been paid to
community based integrated interventions for earlier
stages of the disease or before it has developed.
Though there has been some progress with case
based or hospital based interventions (such as
improvements in exercise capacity, forced expiratory
volume inone second(FEV1), and healthrelatedqual-
ity of life, fewer admissions to hospital and acute
exacerbations, and lower all cause mortality),
6-10 the
efficacy of such efforts are limited in the prevention
of COPD among the general population in China.
Few patients are diagnosed until they develop severe
symptomsand signs, and pulmonary functiontests are
not routinely performed.
4
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gratedinterventionstudytoestablishareliablestrategy
for prevention and management of COPD at its early
stages or before its development.
METHODS
Sampling and randomisation strategy
This community based cluster randomised controlled
trialranfromSeptember2002toMay2007inGuangz-
hou city, China. A multistage randomised sampling
strategy was used. Based on our previous epidemiolo-
gical study,
4 we used computer generated random
selection to select one district (Liwang) from 12 dis-
trictsinGuangzhoucityandtwocommunities(Xichun
and Nanyuan) from nine comparable communities in
the selected district (Liwang). Each was assigned to
intervention or control by simple randomisation (a
cointoss).Wethenusedacomputergeneratedrandom
list to randomly select five of 15 healthcare units in
Xichun and five of 17 healthcare units in Nanyuan
for baseline survey. Two of the 10 healthcare units
wereexcludedbecausetheydidnotcompletethebase-
linesurveyorrefusedthefollow-upsteps.Ahealthcare
unit is a typical office unit in the community. From all
the people in the units aged 40 and over, we selected
about half (n=1062) using a systematic sampling
method according to the house number. All sampled
subjects were invited to participate in the study by a
phone call or home visits. We allocated 872 people
who fulfilled the inclusion criteria to integrated inter-
vention or usual care in local communities. They
underwent follow-up interviews with questionnaires
and spirometry tests in the same hospital at baseline
and follow-up survey. We also evaluated improve-
ments in awareness of health knowledge related to
COPD in random samples drawn from the two com-
munities by using the same systematic sampling
method (house number).
Participants
All included participants aged40-89 in thesetwo com-
munities underwent a baseline screening survey to
evaluate their potential to complete all the acceptable
spirometry tests. They then completed questionnaires
and gave written informed consent. Exclusion criteria
included diagnosis with active tuberculosis, asthma or
obvious bronchiectasis, cystic fibrosis, interstitial lung
disease, or pulmonary thromboembolic disease;
malignant tumour; history of thoracotomy with pul-
monaryresection;anduncontrolledorseriousdiseases
and others that could potentially affect the spirometry
test. Participants were lost to follow-up if we could not
contactthemortheyhadmovedtoanotherplace,with-
drewconsent,refusedtoproceed,hadinvaliddata,and
were unable to complete the study.
Integrated intervention
Three groups in the intervention community
(“healthy” population, high risk group, and patients
with COPD classified by a baseline investigation)
received the integrated intervention, including sys-
tematic health education and intensive and individua-
lised intervention, treatment, and rehabilitation. To
improve outdoor air quality in the intervention com-
munity, residents and the research team made inten-
sive appeals to the local administration for relocation
and technological upgrading of a neighbourhood
cement factory. Because of these joint efforts, the
cement factory received technological upgrading tar-
geted to reduce air pollution and, in 2005, during the
second year and third year of the intervention, relo-
cated to suburban area more than 70 km away.
Allparticipantsunderwentregularsystematichealth
education—with health manuals, bulletins, broadcast
television, video, networks, lectures, free consultation,
and holding of relevant knowledge competitions—
aimed at improving knowledge about COPD, elimi-
nating unhealthy habits and behaviours, and improv-
ing indoor and outdoor air quality.
To maximise the effects of the intervention, indivi-
duals withCOPD and those at highrisk received addi-
tional and intensive interventions quarterly in the first
year and annually in the next three years. These con-
sistedofadviceandinstructionsforsmokingcessation,
recommendations for better stoves, kitchen ventila-
tion, work environment and living environment, and
encouragement on adequate exercises. For smoking
cessation we made smokers aware of the adverse
effects of smoking on health and the benefits of not
smoking, then assessed each smoker’s willing to stop
smokingandpersuadedthemtoquit.Finally,wemade
personalised plans for each smoker who was willing to
quit smoking. Regular telephone or home visits were
performed every three months in the first year and
annually thereafter to check smoking status and expo-
sure to other risk factors, as well as to encourage com-
pliance. To prevent relapses, we held advisory and
recreational activities, lectures, and provided psycho-
social support to help and teach smokers how to cope
withwithdrawalsymptomssuchasstressandincreases
Table 1 |Baseline characteristics within healthcare units. Figures are numbers (percentages)
unless stated otherwise
Intervention community Control community
No of units 4 4
Total targeted population aged >40 2432 2544
Mean (SD) population aged >40 per unit 608 (43) 636 (42)
Mean (SD) annual income* per unit 17 425 (608) 17 031 (190)
Men 1218 (50) 1269 (50)
Age ≥60 994 (41) 1071 (42)
<6 years’ education 970 (40) 1043 (41)
Current smokers 203 (22) 209 (23)
Aware of COPD†‡ 40 (20) 37 (18)
Aware of hazards of smoking†:
Not aware 37 (18) 38 (18)
Know a little 76 (37) 93 (39)
Know more 90 (44) 90 (43)
COPD=chronic obstructive pulmonary disease.
*yuan/person/year; 1 yuan=£0.09, €0.11, $0.15.
†Data from random sample of 424 (203 in intervention community, 221 in control community) who completed
short questionnaire of knowledge on health.
‡Data before intervention were missing for two people.
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replacement therapy (such as smoking cessation tea
and patches) was recommended to relieve cravings
for tobacco and withdrawal symptoms.
In addition, eligible patients with COPD were regu-
larly prescribed a compound bronchodilator (Combi-
vent; salbutamol 120 μg/puff and ipratropium 20 μg/
puff) for a year and received quarterly visits. Pulmon-
aryrehabilitation(suchasphysicalexercise,pursedlip
breathing, and abdominal breathing),
9 low carbohy-
drateandhighproteindiets,andothernon-pharmaco-
logical treatments were also recommend, and patients
were helped to make plans in terms of training meth-
ods, duration of exercise, and intensity according to
guideline.The box summarisesthe content of the inte-
grated intervention.
Usual care
Participants in control communities were treated by
healthcare providers or general practitioners in the
usual manner. In case of deterioration, participants
were treated with drugs by following the guidelines
from the global initiative for chronic obstructive lung
disease (GOLD) or referral to a respiratory specialist.
The content and number of usual care services were
not standardised.
Baseline and follow-up survey and outcomes measurement
All participants filled in questionnaires and underwent
spirometry at the baseline and at annual follow-up sur-
vey.Considerableeffortsweremadetoensurehighqual-
ity data (see appendix 1 on bmj.com). Our primary
outcome was the annual rate of decline in FEV1 before
useofabronchodilatorinthetwocommunities.Thesec-
ondary outcomes included changes in cumulative inci-
dence rate, cumulative case death rate for COPD,
change in awareness of knowledge related to COPD,
and change of risk factors for COPD (such as active and
passive smoking, outdoor air pollution, living and work-
ing environment) from baseline in the two communities.
Questionnaires
Thequestionnairesusedatbaselineandfollow-upvisits
had previously been used in the Burden of Obstructive
Lung Disease study in Guangzhou
3 and COPD epide-
miological survey in China
411 (see appendix 2 on
bmj.com). Additional questionnaires (COPD manage-
ment and St George’s respiratory questionnaire,
SGRQ)wereusedforpatientswithCOPD.Weassessed
and classified changes in risk factors (such asactiveand
passivesmoking,outdoorairpollution,livingandwork-
ing environment) from baseline as improved, no
change, or worse, based on participants’ self report.
From 2002 to 2007 the local bureau of environmental
protection and environmental monitoring centre con-
tinuously measured concentrations of sulphur dioxide
(SO2),nitrogendioxide(NO2),dustdeposition,andsul-
phation rate with an auto-monitoring system.
We classified participants’ smoking status at each
visit as never smoked, smoking cessation (namely, for-
mer smoking), and current smoker. Participants who
had smoked for at least six months or had smoked at
least 100 cigarettes in their lifetime were defined as an
ever smoker,
1213 otherwise they were classed as never
smoking.Currentsmokerswerethosewhoweresmok-
ing tobacco products at the time of the survey and
included continual and intermittent smokers and
those who had quit but restarted or relapsed or had
quit but for less than six months. Smoking cessation
(former smoking) was defined as having not smoked
tobacco products for at least six months at the time of
survey. We give the rate of smoking cessation during
the study period as the ratio of numbers who gave up
smoking during the study period to the numbers of
current smokers at baseline. Environmental tobacco
smoke was assessed by asking participants whether
they could smell tobacco smoke at home or at work
for at least an hour a day at each visit.
13 We classified
this by improvement (including no exposure and
decreasedexposurefrombaseline)ornoimprovement
(thesameandincreasedexposurefrombaseline)based
on self reports. Exposure to occupational dusts/gases/
fumesformorethanayearoveraparticipant’slifetime
was deemed as having occupational exposure.
Spirometry
Trained technicians performed spirometry in accor-
dancewiththecriteriarecommendedbytheAmerican
Components and timings of integrated intervention
All participants (healthy population, those at high risk of COPD, patients with COPD)
Systematic health education
Items or components:
 Smoking hazards and instruction for smoking cessation
 Knowledge of COPD and relative risk factors
Scheme or timings:
 Health manuals, bulletins, etc, in public places quarterly
 A lecture and a large scale free consultation twice a year
 A competition of knowledge and free spirometry annually
Participants at high risk of COPD, patients with COPD
Intensive and individualised interventions
Items or components:
 Advice and instruction for smoking cessation
 Advice to improve air pollution and work environment
 Encouragement to exercise and improvement in living environment
Scheme or timing:
 Alecture,aclubactivity,andavisitquarterlyinthefirstyearandannuallythereafter
Patients with COPD only
Treatment and rehabilitation
Items or components:
 Treatment with compound bronchodilator for a year
 Advice and guidance for individualised rehabilitation, drug use, and diet
 Questionnaire and spirometry quarterly in the first year and annually thereafter
Scheme or timing
 A visit each quarter in the first year for treatment with compound bronchodilator,
advice, and guidance
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14 and the Europe Respiratory
Society.
15 At least three acceptable and two reproduci-
ble measurements (that is, largest and next largest
values of forced vital capacity (FVC) and FEV1 within
150 ml or 5%) that met with the criteria
1415 were
required for each individual. The largest value of
FVC and FEV1 was reported (see appendix 1 on
bmj.com). To minimise the variation of the results, on
each of the four testing days during the four year study
(one day a year) spirometry was performed for each
participant at about the same time of day. The use of
short and long acting bronchodilators was prohibited
within 12 or 24 hours before the test, respectively. A
portable spirometer (Micro Medical, Chatham, Kent)
was used and the test was done after inhalation of 400
μg of salbutamol for 15-20 minutes (Ventolin,
GlaxoSmithKline) via a 500 ml spacer for those parti-
cipants whose FEV1/FVC ratio before bronchodila-
tion was <70%. Definition of COPD and its severity
stages were according to the global initiative for
chronic obstructive lung disease.
16 We used reference
values from the European Coal and Steel Community
1993 for predicted values of FEV1, adjusted with con-
version factors for the Chinese population (male 0.95
and female 0.93).
17
Statistical analysis
To detect the difference of 20 (SD 80) ml in FEV1
between two groups with 80% power, a two sided
type I error of 5%, a design effect of 2.2, and an intra-
cluster correlation coefficient (ICC or ρ, defined as the
ratio of the variance between groups to the total var-
iance) of 0.012 based on a pilot study, we calculated
that we needed eight clusters of 130 participants
accordingtousualformula,
18allowing20%lossduring
follow-up. The statistical analysis was performed with
the SAS version 9.1 software (SAS Institute, Cary,
NC).
Weincludedintheanalysesallrecruitedparticipants
who had received the allocated intervention or usual
care, except those without any acceptable observation
data after randomisation. Baselinecharacteristics were
evaluated with a t test or analysis of variance for con-
tinuous variables and a χ
2 test for dichotomous vari-
ables. Improvements in awareness and risk factors for
COPD between the two communities were analysed
with hierarchical logistic models, taking account of
theclusteringnatureofthedata.Thelatestvalidvalues
withrespecttochangeofawarenessandriskfactorsfor
COPD were regarded as the endpoint values for those
who did not complete follow-up.
Preliminary data analysis showed that the pattern of
change in absolute values of FEV1 (ml), percentage of
predicted value, and FEV1/FVC ratio (%) from base-
line was about linear and varied according to baseline
data. To access longitudinal changes of FEV1 (often
called FEV1 ‘‘slope’’) between the intervention and
control community, we applied SAS’s Proc Mixed
procedure,whichadmitsmissedvalues,tobuildmulti-
level mixed models by adjusting for confounding and
clustering effects. Potential confounders were taken
into account, and we included baseline FEV1 (or
FEV1/FVC ratio), age,sex, education,smoking status,
environmental tobacco smoke, COPD, body mass
index (BMI), and occupational exposure to dusty/
gases/fumes in the final model. The selection of the
appropriate type of covariance structure was accom-
plished by considering the biological features of the
outcome variable and also by choosing the smallest
Akaike’sinformationcriterion(AIC)afterfittingmod-
els with alternative covariance structures. The final
models included an auto regressive order 1 structure
covariance (AR(1)) to count for serial correlation of
FEV1 and FEV1/FVC within individuals and an
unstructured covariance to account for random varia-
tion in the intercept and slope parameters between
Community allocated to usual care (n=1)
  (4 healthcare units, 539 participants)
Received allocated intervention
  (4 healthcare units, 436 participants)
Did not receive allocated usual care
  (0 healthcare units, 103 participants)
    Unreachable/died before intervention
      (n=33, 6%)
    Refused (n=46, 9%)
    Invalid data at baseline survey (n=24, 5%)
Community allocated to intervention (n=1)
  (4 healthcare units, 523 participants)
Received allocated intervention
  (4 healthcare units, 436 participants)
Did not receive allocated intervention
  (0 healthcare units, 87 participants)
    Unreachable/died before intervention
      (n=30, 6%)
    Refused (n=27, 5%)
    Invalid data at baseline survey (n=30, 6%)
Districts randomly selected from 12 districts in Guangzhou city (n=1, 9 communities)
Communities randomly selected (n=2, 32 healthcare units)
Communities randomised (n=2)
Healthcare units randomly selected for baseline survey (n=10, 5 per community)
Healthcare units uncompleted/refused (n=2)
Baseline survey
Healthcare units enrolled to intervention (n=8, 4 per community)
Enrolment
Allocation
Completed follow-up:
  1 year: 428 participants
  2 year: 415 participants
  3 year: 414 participants
  4 year: 410 participants
Uncompleted follow-up participants:
  1 year: 6 missing; 2 withdrew consent; 0 died
    (total 8)
  2 year: 15 missing; 3 withdrew consent; 3 died
    (total 21)
  3 year: 10 missing; 3 withdrew consent; 9 died
    (total 22)
  4 year: 8 missing; 3 withdrew consent; 15 died
    (total 26)
Completed follow-up:
  1 year: 417 participants
  2 year: 409 participants
  3 year: 401 participants
  4 year: 409 participants
Uncompleted follow-up participants:
  1 year: 16 missing; 3 withdrew consent; 0 died
    (total 19)
  2 year: 22 missing; 4 withdrew consent; 1 died
    (total 27)
  3 year: 25 missing; 6 withdrew consent; 4 died
    (total 35)
  4 year: 15 missing; 6 withdrew consent; 6 died
    (total 27)
Follow-up
Analysis (4 healthcare units):
  Questionnaires (n=436)
  Spirometry (n=431)
Excluded from spirometry analysis
  5 with invalid data
Analysis (4 healthcare units):
  Questionnaires (n=436)
  Spirometry (n=429)
Excluded from spirometry analysis
  7 with invalid data
Analysis
Fig 1 | Flow of participants through trial. Missing indicates participants with missing data
because of failure of contact, being out, or inability to finish spirometry test; they might attend
next follow-up visits. Withdrew indicates cumulative number of participants who withdrew
consent (refusal); they were invited to complete investigation with questionnaire before
dropping out
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repeated in subgroups.
Weusedamixedmodeltocomparethechangeinair
pollutants (log transformed) in the two communities.
As preliminary analysis showed significant or close to
significant correlations between pairs of pollutants
(data not shown), they can be regarded as a correlated
“package” of pollutants with a similar pattern relative
to each other across the four year study period. We
extracted a variable to represent these air pollutants
using factor analysis for SO2,N O 2, dust deposition,
and sulphation rate. The correlation of adjusted FEV1
at each year with average level of air pollutants from
baseline was analysed with partial correlations analy-
sis. Significance was set at P<0.05.
RESULTS
Baseline characteristics and follow-up rate
Of 1062 sampled participants, 872 (82%) who fulfilled
the criteria of study were allocated intervention or
usual care. Of these, 845 (80%) completed follow-up
at the first year, 824 (78%) at the second year, 815
(77%) at the third year, and 819 (77%) at the fourth
year. A total of 872 (82%) completed the baseline sur-
vey and at least one follow-up investigation with ques-
tionnaires (83% in the intervention community and
81% in the control community), and 860 (80%) had
acceptable data for spirometry test from at least two
follow-up visits (including baseline) (82% in the inter-
vention community and 80% in the control commu-
nity) (fig 1). There were 840, 822, and 793
participants who completed an acceptable spirometry
test for three, four, and five years (including baseline),
respectively.
There was no difference in causes of allocation fail-
ure between the two communities (P=0.11, fig 1) and
nodifferenceinthemainbasicdemographiccharacter-
istics (see table A in appendix 3 on bmj.com). There
was a significant difference in causes of uncompleted
follow-up (dropping out) for spirometry tests between
thecommunitiesattheendofstudy(P=0.03,fig1).The
twocommunitiesweredrawnfromasingledistrictand
were similar in socioeconomic status (that is, annual
averaged income and education level), availability of
and access to health services, current smoking preva-
lence, awareness of COPD, and main demography at
baseline(table 1).Atbaselinetheinterventioncommu-
nity had a higher concentration of SO2 and sulphation
rate in outdoor air than the control community
(P<0.001 and P=0.018, respectively), but there was
no difference at the end of study (fig 2). Compared
with the control community, the intervention commu-
nity had a greater rate of decline in SO2 concentration
(0.051 µg/m
3 per year (95% confidence interval 0.019
to0.083)P=0.003)anddustdeposition(0.051(0.019to
0.083) kg/km
2/month per year, P=0.003) during fol-
low-up,andtherewasa differenceofborderlinesignif-
icance between the two communities in the slope of
concentration of NO2 (0.033 (−0.013 to 0.079) µg/m
3
per year, P=0.092) and sulphation rate (0.020 (−0.001
to 0.041) µgS O 3/100 cm
2 PbO2/day/year, P=0.059).
Most baseline demographic characteristics of parti-
cipants who completed questionnaires during follow-
up were comparable between the two communities,
except for occupational dusts/gases/fumes exposure
(P<0.001) (table 2). Similar results were observed
among those 860 people who had completed accepta-
ble spirometry tests (data not shown).
FEV1 and FEV1/FVC ratio
During follow-up, the mean rate of decline in FEV1
was about 19 ml and 0.9% of the predicted value per
Table 2 |Baseline characteristics of participants randomly selected from two communities.
Figures are numbers (percentages) unless stated otherwise
Interventioncommunity Control community
No of participants 436 436
Men 211 (48) 188 (43)
Age (years):
Mean (SD) 60.15 (11.31) 60.38 (11.53)
<60 205 (47) 192 (44)
≥60 231 (53) 244 (56)
Years of education:
<6 187 (43) 205 (47)
6-9 106 (24) 113 (26)
≥10 143 (33) 118 (27)
BMI:
Mean (SD) 22.89 (3.45) 22.77 (3.66)
<18.5 40 (9) 42 (10)
≥18.5 396 (91) 394 (90)
Mean (SD) FEV1 (l) 2.03 (0.62) 2.04 (0.63)
Mean (SD) % predicted FEV1 88.72 (19.45) 90.91 (20.69)
Mean (SD) FVC (l) 2.59 (0.72) 2.56 (0.72)
Mean (SD) % predicted FVC 94.66 (18.59) 96.20 (18.74)
FEV1/FVC ratio (%)* 78.27 (10.03) 79.44 (9.88)
Distribution of COPD and non-COPD†:
Healthy population 106 (24) 92 (21)
High risk for COPD 282 (65) 291 (67)
Stage I COPD 9 (2) 10 (2)
Stage II COPD 24 (6) 24 (6)
Stage III COPD or over 15 (3) 19 (4)
Reversibility among COPD‡ 5 (10) 7 (13)
Previous diagnosis of respiratory disorders 76 (17) 83 (19)
Respiratory symptoms 157 (36) 153 (35)
Occupational history of dusts/gases/fumes§ 150 (34) 249 (57)
Respiratory infection during childhood 15 (3) 20 (5)
Smoking status at baseline survey:
Never smoker 241 (55) 235 (54)
Smoking cessation 77 (18) 63 (14)
Current smoker 118 (27) 138 (32)
Smoking amounts (pack years) 13.04 (21.39) 14.31 (21.80)
Exposed to environmental tobacco smoke¶ 302 (70) 315 (73)
BMI=body mass index; FEV1=forced expiratory volume in one second; FVC=forced vital capacity; COPD=chronic
obstructive pulmonary disease.
*Lower in participants without COPD in intervention community than in control community (80.71 (7.95) v 82.47
(6.76), P=0.001).
†Post-bronchodilator data used in participants with COPD; bronchodilation not carried out those without COPD.
‡Reversibility of COPD defined as improvement in FEV1 from pre-bronchodilator ≥12% and ≥200 ml post-
bronchodilator.
§Two communities had similar characteristics at baseline except for occupational history of dust/gases/fumes
(P<0.001).
¶Data missing for 12 participants (seven in intervention community and five in control community).
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vention community (49 ml/year v 30 ml/year; 1.2% v
0.3% of predicted values per year). The FEV1/FVC
ratio declined in the control community but not in
the intervention community (0.4% v −0.5% a year).
After adjustment for confounders and clustering
effects,statisticaleffectspersistedforinterventioncom-
munityintherateofdecline(P<0.05,table 3andfig3).
At the end of the study the intervention community
had a significantly greater estimated mean FEV1 and
FEV1/FVCratiothanthecontrolcommunity(P<0.05,
fig 3). In the total population, the differences were
71 ml (95% confidence interval 47 to 94) for FEV1,
3.0% (1.7% to 4.2%) for predicted value, and 3.1%
(2.4% to 3.9%) for FEV1/FVC ratio. Similar results
were observed among participants without COPD,
with figures of 85 ml (61 to 110, 4.3% (3.0% to 5.6%),
and 3.0% (2.3% to 3.8%), respectively (fig 3).
Further subgroup analyses showed similar results in
the rate of decline of FEV1 and the change of FEV1/
FVC ratio with regard to the effects of intervention
among people without COPD (table 3 and fig 3).
Results were also similar in participants at high risk
(see table B in appendix 3 on bmj.com). There was no
significant difference between patients with COPD
from the two communities in the rate of decline of
FEV1 within four years or in FEV1/FVC ratio (table
B in appendix 3 on bmj.com).
As shown in the subgroup analysis of smoking, in
intervention communities the decline in FEV1 values
(both absolute value (ml) and percentage of predicted
value(%predicted))wasslowerinthosewhohadnever
smoked or had quit smoking than in current smokers
after adjustment for confounders and clustering effects
(P<0.05, tableC in appendix3 on bmj.com).A similar
pattern but with no difference in decline of FEV1 was
founded among subgroups by smoking status in the
control community (table C in appendix 3 on
bmj.com).
Further analysis of non-smokers (including never
smokers and former smokers) showed that non-smo-
kers with reported improvement in exposure to envir-
onmental tobacco smoke seemed to have a slower rate
ofdeclineofFEV1by0.6%ofpredictedvalueperyear
thanthosewithoutanyimprovement,afteradjustment
for confounders and clustering effects (table D in
appendix 3 on bmj.com). Non-smokers in the inter-
vention community still had a slower rate of decline
of FEV1 than those in the control community by
23 ml (12 to 33) per year and 1.2% (0.7% to 1.8%) of
predicted value per year) (table D in appendix 3 on
bmj.com). Differences between the two communities
in current smokers were smaller (data not shown).
Changes in awareness of and risk factors for COPD
By the end of the study, awareness of COPD in the
intervention community improved from 20% to 77%
compared with 18% to 22% in the control community
(P<0.001). Similarly, more people reported awareness
of the risks or hazards of cigarette smoking, despite no
significant difference for awareness of COPD and
related risk factors at baseline (table 1 and table 4).
Compared with the control community, more peo-
ple in the intervention community reported an
improvement in outdoor air pollution (27% v 19%),
working conditions (6% v 3%), and environmental
tobaccosmoke(61%v52%)(table 4).Therateofsmok-
ing cessation in intervention community was 21%,
which is higher than that in the control community
(8%) (table 4). Although there were no significant dif-
ferences between the two communities in cumulative
incidence of COPD (both around 4%) and cumulative
deathrateofCOPD(2%v11%),thereweredifferences
in cumulative death rate from all causes in the total
population during follow-up (1% v 3%, P=0.009)
(table 4). We found no overall difference with regard
toqualityoflife(scoresofStGeorge’srespiratoryques-
tionnaire) among patients with COPD between two
communities. Patients with COPD who had received
integrated intervention for a year, however, showed
improvedqualityoflifeasindicatedinsymptomscores
on the respiratory questionnaire and experienced less
exacerbation of COPD compared with those in the
control community (data not shown).
Changes of outdoor air quality
Asshowninfigure2,therewasagreaterdeclineinSO2
concentration (0.051 (0.019 to 0.083) µg/m
3 per year,
P<0.003) and dust deposition (0.051 (0.019 to 0.083)
kg/km
2/month per year, P<0.003) in the intervention
community than in the control community. There
were borderline differences between the two commu-
nities in the slope of concentration of NO2 (0.033
(−0.013 to 0.079) µg/m
3 per year, P>0.09) and sulpha-
tion rate (0.020 (−0.001 to 0.041) µgS O 3/100 cm
2
PbO2/day/year, P>0.05). These results indicate that
outdoorairqualitywassignificantlyimprovedininter-
vention community compared with the control com-
munity.
DISCUSSION
Principal findings and comparison
Community based integrated intervention at earlier
stages of COPD and before its development could sig-
nificantlyslowthedeclineinFEV1.Toourknowledge,
Table 3 |Difference between two communities in annual rate of decline in FEV1 (ml/year,
predicted %/year) and FEV1/FVC ratio (%/year) in participants aged ≥40
Intervention
community
Control
community Adjusted difference*
No Mean (SE) No Mean (SE) Mean (95% CI) P value
Total population
FEV1 (ml/year) 429 30 (3) 431 49 (3) 19 (3 to 36) 0.023
FEV1 (predicted %/year) 429 0.3 (0.2) 431 1.2 (0.2) 0.9 (0.1 to 1.8) 0.033
FEV1/FVC (%/year) 429 −0.5 (0.1) 431 0.4 (0.1) 0.6 (0.1 to 1.2) 0.029
Participants without COPD
FEV1 (ml/year) 382 26 (3) 379 50 (3) 20 (3 to 37) 0.025
FEV1 (predicted %/year) 382 0.1 (0.2) 379 1.2 (0.2) 1.1(0.2 to 2.0) 0.021
FEV1/FVC (%/year) 382 −0.5 (0.1) 379 0.4 (0.1) 0.7 (0.1 to 1.2) 0.019
*Adjusted for baseline FEV1 (or FEV1/FVC), age, sex, education, smoking status, COPD, BMI (body mass index),
and occupational exposure to dusty/gases/fumes) and clustering effects.
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grated intervention on COPD at the community level.
The multiple risk factor intervention trial (MRFIT),
19
which focused on coronary heart disease, found no
overall differences in the rate of decline in FEV1
betweentwocommunities(usualcareandspecialinter-
vention that included an intensive smoking cessation
programme), but FEV1 declined slowly among smo-
kers who did not take β blockers in the tobacco cessa-
tion intervention group compared with controls. In
LungHealthStudy,
20aggressivesmokinginterventions
were given to smokers with mild COPD, and this
resulted in a slower decline in FEV1 in the first year
between the two groups, but there were no differences
in the next three years. In contrast, our community
based interventions targeted more aspects of COPD
management and prevention at its earlier stages or
before development. As a result, we saw a slower rate
of decline in FEV1 among participants in the inter-
vention community than in the control community.
Meanwhile, there was an improvement in FEV1/FVC
ratio among participants in intervention community,
especially among those at high risk of COPD.
The benefits of our integrated intervention could
have resulted from a combination of smoking cessa-
tion, efforts to improve environmental air quality, self
management training for prevention of COPD, and
other positive factors.
Smoking
Smoking accelerates the decline in FEV1, but it can be
reversed by quitting smoking.
619-23 In our study there
wasagreatercessationrateintheinterventioncommu-
nity than in the control community (21% v 8%). Cessa-
tion was associated with a reduced rate of decline in
FEV1(by−27ml/year)intheinterventioncommunity
(table C in appendix 3 on bmj.com). In the control
community, there was no significant difference in
annual rate of decline in FEV1 between those who
did and did not stop smoking, which could be
explained by the low numbers of participants who
had quit smoking and the fact that some of them gave
upsmokingbecauseofworseninghealthstatus.There-
fore, there seems little question that smoking cessation
greatlycontributedtotheoutcomeoftheintervention.
Other factors besides smoking cessation should also
strengthen the positive benefits of intervention. We
found a significant difference in the rate of decline in
FEV1 between the two communities after adjustment
for smoking cessation, as well as in non-smokers(table
Dinappendix3onbmj.com).Asshowninourresults,
more people reported having improved exposure to
environmental tobacco smoke from baseline in the
intervention community than in control community
duringfollow-up.Thosewhoreportedhavingreduced
exposure to environmental tobacco smoke at the end
ofstudyhadaslowerrateofdeclineinFEV1thanthose
without reduced exposure (table D in appendix 3 on
bmj.com). These observations indicated that changes
in exposure to environmental tobacco smoke might
have contributed to the effects of intervention.
Air pollution
As an important part of the community based inter-
vention programme and after joint efforts of members
of the study team, public, and government, a neigh-
bourhood cement factory near the intervention com-
munitywaseventuallyrelocatedandupgradedin2005
withthemainpurposeofdecreasingairpollution.This
resulting improvement in outdoor air pollution was
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Fig 2 | Annual log mean levels of air pollutants in intervention and control communities, 2002-2007, with 95% confidence
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ing site in the intervention community designated by
thelocalbureauofenvironmental protection(fig2). In
contrast, data from the monitoring site in the control
community showed no improvement in air quality.
Afteradjustmentfor potentialconfoundersand cluster
effects,therewerestillsignificantdifferencesinthesur-
rogates for the change in outdoor air quality between
the two communities, and similar results were
observed among those who had never smoked (table
D in appendix 3 on bmj.com). In addition, there was
significant correlation between adjusted FEV1 and
FEV1/FVC ratio and averaged air pollutants over
time (table E in appendix 3 on bmj.com). Therefore,
improvement in air pollution within the intervention
communityshouldalso havecontributedtotheslower
declineinFEV1,whichisconsistentwithpreviouspub-
lished literature.
24
Education and knowledge
Thoughhealtheducationdidnotseemtohaveobvious
and directly positive effects on the rate of decline in
FEV1 (data not shown), previous trials have shown
thatitcanhelptoreduceexacerbationofandmortality
from COPD and improve quality of life.
92526As lower
respiratory disorders or acute exacerbations of COPD
also promote decline in FEV1 in current smokers with
mildCOPD,
27reductioninacuteexacerbationsshould
also havea positiveeffectondeclineofFEV1.Further-
more,asCOPDisconsideredadiseaseinwhichlimita-
tionofairflowassociatedwithharmfulgasesandfumes
is not fully reversible, education targeted at avoidance
of risk factors might have played an important role in
reducing the decline of FEV1. At baseline 78% of the
participantsknewlittleaboutCOPDandover65%had
never received health education. This poor level of
COPD prevention among people at baseline could
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Fig 3 | Estimated mean FEV1 (ml and % predicted) and FEV1/FVC ratio (%) over time in both communities among total
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designed health education programme in our inte-
grated intervention.
Strengths and limitation of the study
Our integrated community based intervention
achieved positive effects, especially for people at high
riskofCOPD.AsCOPDisadiseasethatcanbecaused
by multiple factors, an integrated intervention, which
wasformedandrefinedfrompublishedmethods(such
as smoking cessation, reduce of air pollution,
rehabilitation, nutrition support, drug treatment, and
health education),
6-91920 should be more effective
regarding development and progression of the disease
than a single intervention targeted at a sole factor.
COPD has a long term course with chronic progres-
sion and is often underdiagnosed, and thus a commu-
nity based integrated intervention at earlier stages or
before development of COPD would have more
impact than a hospital intervention among patients
who have already developed moderately or severely
symptomatic COPD. Our hypothesis is consistent
with the results of several recent studies.
28-30 Thesestu-
dies have shown that FEV1 declined more rapidly in
patients with milder COPD, indicating that more
attention should be paid to patients with earlier stage
disease. Our results further emphasise the importance
of intervention before the development of COPD.
Our study had certain limitations. Firstly, fewer par-
ticipants in the intervention community had occupa-
tional exposure to dust/gases/fumes at baseline. We
consider that this imbalance did not compromise our
conclusionbecausewefoundasignificantlyslowerrate
ofdeclineinFEV1intheinterventioncommunityeven
afteradjustmentforthesefactors.Thiswasalsothecase
in further analyses stratified by occupational exposure
to dust/gases/fumes (figA in appendix4onbmj.com).
Secondly, changes in risk factors such as smoking sta-
tus were not based on laboratory measurement but on
self report. This did not change our conclusions as we
also obtained information from close family members
of the participants. Our results also showed that smok-
ing cessation slowed the rate of decline in FEV1 (table
B in appendix 3 on bmj.com), confirming results of
other studies.
619-21 In addition, despite there being a
correlation between adjusted FEV1 and air pollutants
overtime(tableEinappendix3onbmj.com),wecould
not further confirm the correlation of annual rate of
decline in FEV1 and change of outdoor air quality
because we recruited only two communities. Finally,
we evaluated the annual decline of FEV1 only before
use of a bronchodilator, not after, because a broncho-
dilator test was not performed among patients without
COPD at baseline. COPD was defined by a FEV1/
FVC ratio of below 0.7 after use of bronchodilator.
This criterion, however, could result in overdiagnosis
in older people and underdiagnosis in younger
people.
31 Diagnosis by percentage of FEV1/FVC
ratio below the fifth centile should be more precise.
32
Unfortunately, the lower limit of normal for FEV1/
FVC ratio for people in China is not currently avail-
able.Inaddition,afixedratioofFEV1/FVCbelow0.7
isstillrecommendedbytheglobalinitiativeforchronic
obstructive lung disease (GOLD) and is used by many
other investigators.
333 We therefore used the fixed
ratio of 0.7 for diagnosis of COPD in our study.
Conclusion and implications
In conclusion, this community based integrated inter-
vention helped to prevent and control COPD through
improvedawarenessofCOPD,reducedriskfactorsfor
COPD, and a reduction of the rate of decline in FEV1.
Table 4 |Awareness of health knowledge, change of risk factors, cumulative incidence rate,
and case death rate between two communities after intervention
Intervention
community (n=436)
Controlcommunity
(n=436)
Adjusted odds ratio
(95% CI)* P value
Awareness of COPD†:
Not aware 78 (23) 259 (78) Reference —
Aware 263 (77) 72 (22) 12.13 (8.46 to 17.39) <0.001
Awareness of smoking hazard†:
Not aware 27 (8) 57 (17) Reference —
Know a little 125 (37) 125 (38) 2.11 (1.25 to 3.56) 0.005
Know more 189 (55) 149 (45) 2.68 (1.61 to 4.44) <0.001
Outdoor air pollution‡:
Improved 115 (27) 83 (19) 1.42 (1.02 to 1.98) 0.039
No change 241 (56) 247 (57) Reference —
Worsened 76 (18) 105 (24) 0.74 (0.53 to 1.05) 0.091
Working conditions:
Improved 24 (6) 14 (3) 1.73 (0.88 to 3.39) 0.113
No change 407 (93) 410 (94) Reference —
Worsened 5 (1) 12 (3) 0.42 (0.15 to 1.20) 0.106
Environmental exposure to tobacco smoke§:
Improved 262 (61) 222 (52) 1.48 (1.32 to 1.68) <0.001
Not improved 167 (39) 209 (49) Reference —
Smoking status at end of study:
Never smoker 241 (55) 235 (54) Reference —
Current smoker¶ 95 (22) 129 (30) 0.72 (0.52 to 0.99) 0.045
Stopped smoking 100 (23) 72 (17) 1.36 (0.95 to 1.93) 0.092
Stopped smoking during study period:
No 93 (79) 127 (92) Reference —
Yes 25 (21) 11 (8) 3.10 (1.44 to 6.67) <0.004
Cumulative incidence of COPD**
Yes 16 (4) 16 (4) 0.98 (0.49 to 2.00) 0.964
No 369 (96) 358 (96) Reference —
Cumulative deaths from COPD
Yes 1 (2) 6 (11) 0.17 (0.02 to 1.50) 0.120
No 47 (98) 47 (89) Reference —
Cumulative deaths from all causes
Yes 6 (1) 15 (3) 0.23 (0.08 to 0.69) <0.009
No 430 (99) 421 (97) Reference —
*Adjusted for clustering effects. Odds ratio >1 means that over four years more people in intervention
community than control community reported improvement in variables. After adjustment for clustering effect,
when variables were considered as ordered categories and cumulative logit model was used, odd ratios were
1.66 (1.24 to 2.22, P<0.001) for awareness of hazards of smoking, 1.52 (1.17 to 1.97, P<0.002) for outdoor air
pollution, and 1.94 (1.09 to 3.44, P=0.024) for working conditions.
†After intervention 341 in intervention community and 331 in control community randomly sampled from entire
population completed short questionnaire of knowledge on health.
‡Data missing for four in intervention community and one in control community.
§Data missing for seven in intervention community and five in control community.
¶Four former smokers at baseline (two in each community) had started smoking at end of study.
**Diagnosis of COPD was according to global obstructive lung disease in 12 participants. Excludes participants
who did not undergo post-bronchodilator test and those with pre-bronchodilator FEV1/FVC ≥70%.
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vention and our experience with it might be culture
andconditionspecific,the outcomesthatsmokingces-
sation,improvementinairpollutants,andreductionin
environmental tobacco smoke have contributed to the
slowing rate of decline in FEV1 should apply through-
out the world.
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